Purple Total Liab vs Retained Earnings Analysis
PPBT Stock | USD 2.74 0.55 25.11% |
Purple Biotech financial indicator trend analysis is much more than just breaking down Purple Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Purple Biotech is a good investment. Please check the relationship between Purple Biotech Total Liab and its Retained Earnings accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.
Total Liab vs Retained Earnings
Total Liab vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Purple Biotech Total Liab account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.
The correlation between Purple Biotech's Total Liab and Retained Earnings is -0.95. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Purple Biotech, assuming nothing else is changed. The correlation between historical values of Purple Biotech's Total Liab and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Purple Biotech are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Liab i.e., Purple Biotech's Total Liab and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.95 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Purple Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Purple Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Enterprise Value is likely to gain to about 11 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.
Purple Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Purple Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Purple Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.7M | 83.8M | 70.2M | 54.6M | 44.3M | 32.4M | |
Other Current Liab | 1.1M | 1.7M | 2.6M | 4.7M | 3.5M | 2.2M | |
Total Current Liabilities | 3.5M | 3.1M | 4.3M | 7.1M | 7.2M | 3.7M | |
Total Stockholder Equity | 10.4M | 79.4M | 64.8M | 46.9M | 34.2M | 27.6M | |
Net Debt | (4.2M) | (10.4M) | (10.1M) | (14.5M) | (14.1M) | (13.4M) | |
Retained Earnings | (49.5M) | (77.5M) | (95.9M) | (117.6M) | (137.5M) | (130.6M) | |
Accounts Payable | 1.2M | 1.2M | 1.5M | 2.1M | 3.5M | 3.7M | |
Cash | 4.4M | 11.2M | 10.9M | 15.0M | 14.5M | 8.4M | |
Cash And Short Term Investments | 6.4M | 57.8M | 47.2M | 32.1M | 15.4M | 19.6M | |
Common Stock Shares Outstanding | 1.9M | 17.2M | 17.8M | 18.5M | 221.3M | 232.4M | |
Liabilities And Stockholders Equity | 14.7M | 83.8M | 70.2M | 54.6M | 44.3M | 32.4M | |
Non Current Liabilities Total | 313K | 953K | 842K | 466K | 2.8M | 3.0M | |
Other Current Assets | 1.9M | 977K | 1.3M | 1.1M | 376K | 357.2K | |
Other Stockholder Equity | 56.9M | 118.9M | 124.0M | 126.4M | 133.2M | 72.8M | |
Total Liab | 3.9M | 4.1M | 5.1M | 7.5M | 10.0M | 10.5M | |
Total Current Assets | 8.3M | 59.3M | 48.5M | 33.3M | 15.8M | 20.9M | |
Accumulated Other Comprehensive Income | 3.1M | 8.0M | 8.8M | 10.1M | 38.5M | 40.4M | |
Property Plant And Equipment Net | 244K | 968K | 896K | 682K | 470K | 409.3K | |
Non Current Assets Total | 6.4M | 24.5M | 21.7M | 21.4M | 28.5M | 29.9M | |
Property Plant And Equipment Gross | 244K | 968K | 896K | 682K | 470K | 409.3K | |
Other Liab | 285K | 265K | 292K | 145K | 130.5K | 124.0K | |
Net Tangible Assets | 4.2M | 58.9M | 44.3M | 26.2M | 30.2M | 24.0M | |
Short Term Investments | 2.0M | 46.6M | 36.3M | 17.1M | 923K | 876.9K | |
Property Plant Equipment | 244K | 968K | 896K | 682K | 784.3K | 451.2K | |
Net Invested Capital | 10.4M | 79.4M | 64.8M | 46.9M | 34.2M | 39.9M | |
Net Working Capital | 4.8M | 56.2M | 44.2M | 26.2M | 8.6M | 8.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.